Structure

InChI Key OVSQVDMCBVZWGM-QSOFNFLRSA-N
Smiles O=c1c(O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)c(-c2ccc(O)c(O)c2)oc2cc(O)cc(O)c12
InChI
InChI=1S/C21H20O12/c22-6-13-15(27)17(29)18(30)21(32-13)33-20-16(28)14-11(26)4-8(23)5-12(14)31-19(20)7-1-2-9(24)10(25)3-7/h1-5,13,15,17-18,21-27,29-30H,6H2/t13-,15-,17+,18-,21+/m1/s1

Physicochemical Descriptors

Property Name Value
Molecular Formula C21H20O12
Molecular Weight 464.38
AlogP -0.54
Hydrogen Bond Acceptor 12.0
Hydrogen Bond Donor 8.0
Number of Rotational Bond 4.0
Polar Surface Area 210.51
Molecular species ACID
Aromatic Rings 3.0
Heavy Atoms 33.0
Assay Description Organism Bioactivity Reference
Inhibition of rat lung ACE at 38 ug/ml relative to control Rattus norvegicus 0.0 %
Inhibition of rat lung ACE at 56 ug/ml relative to control Rattus norvegicus 0.0 %
Inhibition of rat lung ACE at 75 ug/ml relative to control Rattus norvegicus 9.0 %
Inhibition of rat lung ACE at 113 ug/ml relative to control Rattus norvegicus 3.0 %
Inhibition of rat lung ACE at 150 ug/ml relative to control Rattus norvegicus 19.0 %
Inhibition of rat lung ACE at 225 ug/ml relative to control Rattus norvegicus 19.0 %
Inhibition of rat lung ACE at 300 ug/ml relative to control Rattus norvegicus 133.0 %
Antiprotozoal activity against Entamoeba histolytica HM-1:IMSS trophozoites after 48 hrs by MTT/PMS assay Entamoeba histolytica HM-1:IMSS 14.7 ug.mL-1
Antiprotozoal activity against Giardia lamblia IMSS:0989:1 after 48 hrs by MTT/PMS assay Giardia intestinalis 87.3 ug.mL-1
Antioxidant activity assessed as DPPH free radical scavenging activity relative to control None 16.6 ug.mL-1
Antioxidant activity assessed as superoxide anion scavenging activity by xanthine oxidase oxidation system relative to control None 3.4 ug.mL-1
Antioxidant activity assessed as inhibition of 2,2'-azobis(2-amidinopropane)dihydrochloride-induced lipid peroxidation at 3.125 ug/ml by ferric thiocyanate system relative to control None 49.9 %
Inhibition of TPA-induced EBV-early antigen activation in human Raji cells relative to TPA Human herpesvirus 4 570.0 molar ratio
Antiviral activity against RSV Long in MDCK cells assessed as inhibition of virus-induced cytopathic effect Respiratory syncytial virus 5.9 ug.mL-1
Cytotoxicity against MDCK cells Canis lupus familiaris 23.4 ug.mL-1
Antiviral activity against PIV3 in MDCK cells assessed as inhibition of virus-induced cytopathic effect Human parainfluenza virus 3 23.4 ug.mL-1
Antiviral activity against influenza virus type A H1N1 in MDCK cells assessed as inhibition of virus-induced cytopathic effect Influenza A virus 500.0 ug.mL-1
Inhibition of COX2 at 2.5 ug/mL None 25.0 %
Antioxidant activity assessed as DPPH radical scavenging activity after 10 mins None 20.4 ug.mL-1
Cytotoxicity against human Jurkat T cells after 36 hrs by MTT assay Homo sapiens 100.0 ug.mL-1
Inhibition of Hepatitic C virus NS3/4A protease by FRET assay Hepatitis C virus 10.0 ug.mL-1
Inhibition of electric eel AChE at 2 mg/ml by Ellman's method Electrophorus electricus 0.12 %
Inhibition of horse BChE at 2 mg/ml by Ellman's method Equus caballus 2.54 %
Antioxidant activity assessed as inhibition of DPPH radical production after 30 min by microplate assay None 24.02 ug.mL-1
Antioxidant activity assessed as inhibition of DPPH radical production at 54.05 ug/ml after 30 min by microplate assay None 86.09 %
Inhibition ofRattus norvegicus alpha-glucosidase isolated from intestine using PNPG as substrate at 0.02 uM incubated for 15 min prior to substrate addition measured after 15 min by spectrophotometric analysis Rattus norvegicus 50.0 %
Inhibition of alpha-glucosidase (unknown origin) using PNPG as substrate at 0.02 uM incubated for 15 min prior to substrate addition measured after 15 min by spectrophotometric analysis Homo sapiens 14.38 %
Inhibition of tyrosinase (unknown origin) using L-DOPA substrate at 1000 uM Homo sapiens 54.55 %
Inhibition of tyrosinase (unknown origin) using L-DOPA substrate at 100 uM Homo sapiens 40.59 %
Inhibition of tyrosinase (unknown origin) using L-DOPA substrate at 10 uM Homo sapiens 0.0 %
Inhibition of PTP1B (unknown origin) using p-nitrophenyl phosphate as substrate at 100 uM Homo sapiens 50.0 %
Inhibition of TRAP activity in RANKL-induced Balb/c mouse RAW264.7 cells at 10 uM after 1 hr by ELISA relative to control Mus musculus 82.9 %
Inhibition of TRAP activity in Balb/c mouse RAW264.7 cells at 10 uM after 1 hr by ELISA relative to control Mus musculus 168.48 %
Inhibition of TRAP activity in RANKL-induced Balb/c mouse RAW264.7 cells at 1 uM after 1 hr by ELISA relative to control Mus musculus 76.57 %
Inhibition of TRAP activity in Balb/c mouse RAW264.7 cells at 1 uM after 1 hr by ELISA relative to control Mus musculus 155.6 %
Inhibition of sEH (unknown origin) assessed as substrate PHOME hydrolysis at 25 uM after 1 hr by fluorescence method Homo sapiens 40.0 %
Inhibition of porcine pancreatic lipase using p-nitrophenylbutyrate as substrate assessed as formation of p-nitrophenol at 100 uM preincubated for 15 mins followed by substrate addition measured after 15 mins relative to control Sus scrofa 12.6 %
Inhibition of melanogenesis in theophylline-stimulated mouse B16-4A5 cells at 1 uM after 72 hrs by microplate reader analysis relative to control Mus musculus 16.7 %
Inhibition of melanogenesis in theophylline-stimulated mouse B16-4A5 cells at 3 uM after 72 hrs by microplate reader analysis relative to control Mus musculus 33.2 %
Inhibition of melanogenesis in theophylline-stimulated mouse B16-4A5 cells at 10 uM after 72 hrs by microplate reader analysis relative to control Mus musculus 20.7 %
Inhibition of melanogenesis in theophylline-stimulated mouse B16-4A5 cells at 30 uM after 72 hrs by microplate reader analysis relative to control Mus musculus 23.2 %
Inhibition of melanogenesis in theophylline-stimulated mouse B16-4A5 cells at 100 uM after 72 hrs by microplate reader analysis relative to control Mus musculus 20.7 %
Inhibition of mushroom tyrosinase using L-DOPA as substrate assessed as dopaquinone production at 10 uM after 5 mins by microplate reader analysis relative to control Agaricus bisporus 4.4 %
Inhibition of mushroom tyrosinase using L-DOPA as substrate assessed as dopaquinone production at 100 uM after 5 mins by microplate reader analysis relative to control Agaricus bisporus 5.0 %
Inhibition of plasmin (unknown origin) at 100 uM after 18 hrs by arianor mahogany dye-based fibrin plate assay relative to control Homo sapiens -2.5 %
Anti-platelet activity in rat platelet rich plasma assessed as inhibition of ADP and calcium-induced platelet aggregation at 100 uM pre-incubated at 37 degC for 10 mins and measured 30 mins after ADP and calcium addition Rattus norvegicus 36.24 %
Inhibition of alpha-amylase (unknown origin) relative to control Homo sapiens 12.2 %
Inhibition of human recombinant carbonic anhydrase 4 preincubated for 15 mins at room temperature/6 hrs at 4 deg C by stopped-flow CO2 hydration assay Homo sapiens 75.7 nM
Inhibition of human recombinant carbonic anhydrase 7 preincubated for 15 mins at room temperature/6 hrs at 4 deg C by stopped-flow CO2 hydration assay Homo sapiens 3.8 nM
Inhibition of human recombinant carbonic anhydrase 12 preincubated for 15 mins at room temperature/6 hrs at 4 deg C by stopped-flow CO2 hydration assay Homo sapiens 52.1 nM
Inhibition of human recombinant carbonic anhydrase 2 Homo sapiens 410.0 nM
Inhibition of human recombinant carbonic anhydrase 12 Homo sapiens 170.0 nM
Inhibition of Trichomonas vaginalis adenosine-guanosine preferring ribohydrolase after 40 mins Trichomonas vaginalis 300.0 nM
Inhibition of Trichomonas vaginalis adenosine-guanosine preferring ribohydrolase after 40 mins in presence of 0.01% triton X-100 Trichomonas vaginalis 900.0 nM
Antileishmanial activity against amastigote Leishmania amazonensis Leishmania amazonensis 0.78 ug.mL-1
Antichlamydial activity against Chlamydia pneumoniae K7 infected in HL cells assessed as chlamydial inhibition at 50 uM after 70 hrs by fluorescent microscopic analysis Chlamydia pneumoniae 38.0 %
Antibacterial activity against Staphylococcus aureus MRSA ATCC 43300 (CO-ADD:GP_020); MIC in CAMBH media, using NBS plates, by OD(600) Staphylococcus aureus subsp. aureus 18.79 %
Antibacterial activity against Escherichia coli ATCC 25922 (CO-ADD:GN_001); MIC in CAMBH media using NBS plates, by OD(600) Escherichia coli -1.78 %
Antibacterial activity against Klebsiella pneumoniae MDR ATCC 70063 (CO-ADD:GN_003); MIC in CAMBH media using NBS plates, by OD(600) Klebsiella pneumoniae 10.08 %
Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 (CO-ADD:GN_042); MIC in CAMBH media using NBS plates, by OD(600) Pseudomonas aeruginosa 60.53 %
Antibacterial activity against Acinetobacter baumannii ATCC 19606 (CO-ADD:GN_034); MIC in CAMBH media using NBS plates, by OD600 Acinetobacter baumannii 25.15 %
Antifungal activity against Candida albicans ATCC 90028 (CO-ADD:FG_001); MIC in YNB media using NBS plates, by OD630 Candida albicans 1.9 %
Antifungal activity against Cryptococcus neoformans H99 ATCC 208821 (CO-ADD:FG_002); MIC in YNB media using NBS plates, by Resazurin OD(600-570) Cryptococcus neoformans 3.22 %
Inhibition of LSD1 (unknown origin) by fluorescence assay Homo sapiens 950.0 nM
Inhibition of PCSK9 mRNA expression in human HuH7 cells at 2 uM after 24 hrs by qRT-PCR assay relative to control Homo sapiens 20.0 %
Inhibition of ATP synthase in Escherichia coli relative to control Escherichia coli 40.0 %
Hypolipidemic activity against oleic acid/palmitic acid-induced hyperlipidemia in human HepG2 cells assessed as reduction in triglycerides content relative to control group Homo sapiens 30.42 %

Related Entries

Cross References

Resources Reference
ChEBI 68352
ChEMBL CHEMBL250450
DrugBank DB12665
FDA SRS 6HN2PC637T
Human Metabolome Database HMDB0037362
KEGG C05623
PDB HW2
PubChem 5280804
SureChEMBL SCHEMBL181306
ZINC ZINC000004096845